Virtual Meetings 2020

Meet The Professor: Management of Lung Cancer

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

Each 1-hour session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for lung cancer. Each event will employ an identical format that will include the following elements:

  • • Discussion of Steering Committee Members’ Treatment Recommendations
  • • Review of Available Clinical Research Findings
  • • Integration of Interactive Audience Polling Results
MODULE 1 Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation MODULE 2 Anti-PD-1/PD-L1 Antibodies Alone or in Combinations for Metastatic NSCLC MODULE 3 First-Line Treatment of Extensive-Stage Small Cell Lung Cancer MODULE 4 Checkpoint Inhibition in the Management of Locally Advanced NSCLC

Commercial Support
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives

  • Appreciate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with non-small cell lung cancer (NSCLC) with an EGFR tumor mutation, including those with CNS metastases, and consider the effect of this information on current and future clinical practice.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors in combination with VEGFR-targeted therapy for metastatic NSCLC with an EGFR tumor mutation, and discern the potential ramifications of this information for practice and future clinical trial design.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately and safely integrate this strategy into clinical practice.
  • Appraise published research data and current guideline recommendations informing the use of immune checkpoint inhibitors for small cell lung cancer (SCLC), and discern how these agents can be optimally employed in clinical practice.
  • Appreciate available Phase III data investigating the role of durvalumab in combination with platinum-based chemotherapy for newly diagnosed extensive-stage SCLC, and use this information to identify patients who may be appropriate for treatment with this novel approach.
  • Recognize recent FDA approvals and other therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC.
  • Evaluate available and emerging research data documenting the efficacy and safety of anti-PD-1/PD-L1 and anti-CTLA-4 antibody combinations with or without chemotherapy as first-line treatment for NSCLC, and consider the potential roles of these regimens.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.


Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

STEERING COMMITTEE — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ramaswamy Govindan, MD
Professor of Medicine
Director, Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Advisory Committee: Achilles Therapeutics; Consulting Agreements: GenePlus, Horizon.

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: AstraZeneca Pharmaceuticals LP, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, EMD Serono Inc, Foundation Medicine, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Kairos Venture Investments LLC, Lilly, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc, Kairos Venture Investments LLC, Lilly; Contracted Research: AACR-Johnson & Johnson Lung Cancer Innovation Science Grants, American Cancer Society, AstraZeneca Pharmaceuticals LP, Cancer Prevention & Research Institute of Texas, Checkmate Pharmaceuticals, National Cancer Institute at the National Institutes of Health, Spectrum Pharmaceuticals Inc; Patents and Royalties: Bio-Tree Systems Inc, Spectrum Pharmaceuticals Inc.

Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Advisory Committee: Amgen Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committee: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Lilly, Merck, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hospira Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novocure, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Advantagene Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Incyte Corporation, Inovio Pharmaceuticals Inc, Lilly, MacroGenics Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board/Committee: Amgen Inc, Lilly.

Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Medical Director, Thoracic Oncology Program
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
Washington, DC

Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Pfizer Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck.

Professor Tony SK Mok, MD
Chairman, Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Advisory Committee: AbbVie Inc, ACEA Pharma, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cirina, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, G1 Therapeutics, Gritstone Oncology, Guardant Health, geneDecode Co Ltd, Hengrui Therapeutics Inc, Hutchison China MediTech Limited, Ignyta Inc, Incyte Corporation, IQVIA, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation; Consulting Agreements: AbbVie Inc, ACEA Pharma, Alpha Biopharma, Amgen Inc, Amoy Diagnostics Co Ltd, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, Gritstone Oncology, Guardant Health, Hengrui Therapeutics Inc, Ignyta Inc, Incyte Corporation, IQVIA, INMED, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, G1 Therapeutics, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, SFJ Pharmaceuticals, Takeda Oncology, Xcovery.

Joel W Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Stanford Cancer Institute
Stanford University
Palo Alto, California

Advisory Committee: AstraZeneca Pharmaceuticals LP, Calithera Biosciences, Exelixis Inc, Genentech, a member of the Roche Group, Jounce Therapeutics, Lilly, Takeda Pharmaceutical Company Limited; Contracted Research: Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Nektar, Novartis, Takeda Pharmaceutical Company Limited.

Paul K Paik, MD
Associate Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Celgene Corporation, EMD Serono Inc, Lilly; Consulting Agreement and Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology.

Nathan A Pennell, MD, PhD
Professor, Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Cleveland, Ohio

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck; Contracted Research: Altor Bioscience Corp, AstraZeneca Pharmaceuticals LP, Heat Biologics Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Myriad Genetic Laboratories Inc, Spectrum Pharmaceuticals Inc.

Professor Solange Peters, MD, PhD
Head, Medical Oncology
Chair, Thoracic Malignancies
Oncology Department
Lausanne University Hospital (CHUV)
Lausanne, Switzerland

Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, BioInvent International AB, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm Group, F Hoffmann-La Roche Ltd, Foundation Medicine, Illumina Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Takeda Oncology; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Illumina Inc, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: Academic trials.

Lecia V Sequist, MD, MPH
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital Cancer Center
The Landry Family Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis.

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Consulting Agreements: Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Merck, Molecular Templates, Nektar, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Seattle Genetics, Takeda Pharmaceutical Company Limited, Triptych Health Partners, TRM Oncology; Contracted Research: Aeglea BioTherapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, GRAIL, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Takeda Oncology, Transgene, UT Southwestern Medical Center.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.